CV 9103
/ CureVac
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 01, 2017
Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
(ESMO 2017)
- "Safety and immune responses to the predecessor therapy CV9103 encoding 4 of the antigens have been described previously. CV9104 did not improve OS compared to placebo. Additional clinical outcomes and analyses of cellular and humoral immune responses will be presented and impact on further development will be discussed."
Clinical • P1/2 data • Prostate Cancer
1 to 1
Of
1
Go to page
1